-+ 0.00%
-+ 0.00%
-+ 0.00%

VADERIS THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $152 MILLION SERIES B FINANCING AND INITIATION OF THE GLOBAL PHASE 3 HEROIC STUDY OF ENGASERTIB FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA

Reuters·08/11/2026 11:00:19

Please log in to view news